Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions
Nicole J Gormley1, Ann T Farrell1, Richard Pazdur1
1Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
JAMA Oncology
|September 16, 2016
Abstract
No abstract available in PubMed .
